I. OVERVIEW OF THE FUNDING OPPORTUNITY

Program Announcement for the Department of Defense

Defense Health Program

Congressionally Directed Medical Research Programs

Prostate Cancer Research Program

Clinical Consortium Award

Announcement Type: Initial

Funding Opportunity Number: W81XWH-17-PCRP-CCA

Catalog of Federal Domestic Assistance Number: 12.420 Military Medical Research and Development

SUBMISSION AND REVIEW DATES AND TIMES

• Pre-Application Submission Deadline: 5:00 p.m. Eastern time (ET), August 24, 2017

• Application Submission Deadline: 11:59 p.m. ET, September 7, 2017

• End of Application Verification Period: 5:00 p.m. ET, September 12, 2017

• Peer Review: October 2017

• Programmatic Review: January 2018

This Program Announcement must be read in conjunction with the General Application Instructions, version 20170516. The General Applications Instructions document is available for downloading from the Grants.gov funding opportunity announcement by selecting the “Package” tab, clicking “Preview,” and then selecting “Download Instructions.”
# TABLE OF CONTENTS

I. OVERVIEW OF THE FUNDING OPPORTUNITY ....................................................... 1

II. DETAILED INFORMATION ABOUT THE FUNDING OPPORTUNITY ............... 3

   II.A. Program Description ....................................................................................... 3

   II.A.1. FY17 PCRP Overarching Challenges and Focus Areas ......................... 3

   II.B. Award Information .......................................................................................... 4

   II.C. Eligibility Information ..................................................................................... 10

   II.C.1. Eligible Applicants ....................................................................................... 10

   II.C.2. Cost Sharing ................................................................................................ 11

   II.C.3. Other ............................................................................................................ 11

   II.D. Application and Submission Information ..................................................... 11

   II.D.1. Address to Request Application Package ................................................ 11

   II.D.2. Content and Form of the Application Submission ...................................... 12

   II.D.3. Dun and Bradstreet Universal Numbering System (DUNS) Number and System for Award Management (SAM) ................................................. 28

   II.D.4. Submission Dates and Times .................................................................... 28

   II.D.5. Funding Restrictions .................................................................................... 28

   II.D.6. Other Submission Requirements ............................................................... 31

   II.E. Application Review Information .................................................................. 31

   II.E.1. Criteria ......................................................................................................... 31

   II.E.2. Application Review and Selection Process ............................................... 35

   II.E.3. Integrity and Performance Information ..................................................... 36

   II.E.4. Anticipated Announcement and Federal Award Dates ............................ 36

   II.F. Federal Award Administration Information ............................................... 36

   II.F.1. Federal Award Notices .............................................................................. 36

   II.F.2. Administrative and National Policy Requirements .................................. 38

   II.F.3. Reporting ..................................................................................................... 38

   II.G. Federal Awarding Agency Contacts ............................................................. 39

   II.G.1. CDMRP Help Desk ................................................................................... 39

   II.G.2. Grants.gov Contact Center ....................................................................... 39

   II.H. Other Information ......................................................................................... 39

   II.H.1. Program Announcement and General Application Instructions Versions ... 39

   II.H.2. Administrative Actions ............................................................................. 39

   II.H.3. Application Submission Checklist ............................................................ 42

APPENDIX 1: ACRONYM LIST ............................................................................... 43
II. DETAILED INFORMATION ABOUT THE FUNDING OPPORTUNITY

II.A. Program Description

Applications to the Fiscal Year 2017 (FY17) Prostate Cancer Research Program (PCRP) are being solicited for the Defense Health Agency (DHA) J9, Research and Development Directorate, by the U.S. Army Medical Research Acquisition Activity (USAMRAA) using delegated authority provided by United States Code, Title 10, Section 2358 (10 USC 2358). As directed by the Office of the Assistant Secretary of Defense for Health Affairs (OASD[HA]), the DHA manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation. The execution management agent for this Program Announcement is the Congressionally Directed Medical Research Programs (CDMRP). The PCRP was initiated in 1997 to promote innovative research focused on eradicating prostate cancer. Appropriations for the PCRP from FY97 through FY16 totaled $1.53 billion (B). The FY17 appropriation is $90 million (M).

The mission of the FY17 PCRP is to find and fund research that will lead to the elimination of death from prostate cancer and enhance the well-being of men experiencing the impact of the disease. Specifically, the PCRP seeks to promote highly innovative, groundbreaking research; high-impact research with near-term clinical relevance; multidisciplinary, synergistic research; translational studies to support the fluid transfer of knowledge between bench and bedside; research on patient survivorship and quality of life; the next generation of prostate cancer investigators through mentored research; and research on disparities in the incidence and mortality of prostate cancer.

II.A.1. FY17 PCRP Overarching Challenges and Focus Areas

PCRP Overarching Challenges: Consistent with the program’s mission to eliminate death from prostate cancer and enhance the well-being of men experiencing the impact of the disease, investigators are strongly encouraged to address one or more of the following FY17 PCRP Overarching Challenges:

- Distinguish aggressive from indolent disease in men newly diagnosed with prostate cancer
- Develop strategies to prevent progression to lethal prostate cancer
- Develop effective treatments and address mechanisms of resistance for men with high-risk or metastatic prostate cancer
- Develop strategies to optimize the physical and mental health of men with prostate cancer
PCRP Focus Areas (Revised for FY17!): All applications for the FY17 PCRP funding opportunities are also expected to address at least one of the following FY17 PCRP Focus Areas:

- Data Science and Analytics
- Imaging and Targeted Radionuclide Therapy
- Population Science
- Precision Medicine, Screening, and Surveillance
- Survivorship, including Psychosocial Impact on the Patient and Family
- Therapy and Mechanisms of Resistance and Response
- Tumor and Microenvironment Biology

II.B. Award Information

The PCRP Clinical Consortium Award mechanism was first offered in FY05, and again in FY06, FY08, and FY13. In FY16, the Clinical Consortium Research Site Award was offered. A total of 75 Clinical Consortium Award applications have been received, and 42 have been recommended for funding.

The anticipated direct costs budgeted for the entire period of performance for an FY17 PCRP Clinical Consortium Award will not exceed $3,600,000 for the Coordinating Center and will not exceed $600,000 for each Clinical Research Site. Refer to Section II.D.5, Funding Restrictions, for detailed funding information.

The Clinical Consortium Award mechanism provides the support to develop and enhance collaborations and resources necessary for a network of organizations to rapidly execute Phase II or Phase II-linked Phase I (Phase I/II) prostate cancer clinical trials. These trials will include investigations of high-impact, novel therapeutic agents or approaches for the management or treatment of prostate cancer, especially as pertaining to the FY17 PCRP Overarching Challenges. Support from this award is directed toward consortium infrastructure needs rather than direct support of the research itself. In accordance with PCRP goals, the conduct of Phase I/II trials that incorporate investigations of biomarkers for risk assessment, early detection, prediction of aggressiveness, and/or progression of prostate cancer is particularly encouraged.

The principal goal of the Clinical Consortium Award is to combine the efforts of leading investigators to bring to market high-impact, novel therapeutic interventions that will ultimately and significantly decrease the impact of the disease. To facilitate global investigations, Principal Investigators (PIs) from both U.S. and international institutions are encouraged to apply. Submissions from institutions with enhanced access to patients in the Military Health System and/or from disproportionately affected populations (including, but not limited to, socioeconomic status, access to health care, age, geography, race, and ethnicity) are especially encouraged.
The FY17 PCRP Clinical Consortium Award mechanism will be used to select and fund a single Coordinating Center and two Clinical Research Sites. PIs will be required to indicate whether the institution is applying as either the Coordinating Center with a Clinical Research Site or as a Clinical Research Site only. PIs applying as the Coordinating Center, if not selected for funding, have the option to still be considered as a Clinical Research Site only. The Coordinating Center and Clinical Research Sites will be jointly responsible for proposing, selecting, and conducting Phase II and Phase I/II clinical trials focused on prostate cancer therapeutic interventions. The PCRP Clinical Consortium is expected to consist of one Coordinating Center and approximately 8 to 12 Clinical Research Sites. The Coordinating Center and Clinical Research Sites funded by the FY17 PCRP Clinical Consortium Award will work with other currently funded FY16 PCRP Clinical Research Sites. Additional details regarding the structure of the consortium are described in detail below.

The Coordinating Center, in addition to functioning as a Clinical Research Site, will serve as the consortium information and planning nexus providing administrative, operational, and data management support services to participating Clinical Research Sites to implement consortium clinical trials in a timely manner. Responsibilities of the Coordinating Center will include the clinical trial selection process, protocol coordination, regulatory coordination, study management and monitoring, data collection, management and statistics, and intellectual/material property coordination. The Coordinating Center will also be responsible for preparing two clinical trials, with funding already secured, to be initiated by the consortium within the first 3 months of the performance period. All sites (Clinical Research Sites and the Coordinating Center) will be required to participate in at least one of these two initial clinical trials.

Collectively, the Coordinating Center PI and Clinical Research Site PIs will constitute the Clinical Consortium Committee, which will collaboratively develop and maintain a procedure for the selection of clinical trials to be implemented within the consortium. A representative from the PCRP must be invited to meetings of the Clinical Consortium Committee as well as any other formal meetings of the consortium. All sites will be responsible for working collaboratively to identify new clinical trials for implementation. Any site may serve as an entry point for clinical trials that originate from outside the consortium. The Coordinating Center will be responsible for facilitating this entire process. The consortium is strongly encouraged to leverage the Department of Defense (DoD) investment whenever possible by implementing DoD-funded trials.

Key requirements of the Clinical Consortium Award include:

1. Responsibilities of the Consortium Participants: Procedures for the consortium, while proposed by the Coordinating Center, will be fully developed and agreed upon by all participants working collaboratively. At the discretion and expense of the Government, a pre-award planning meeting may be required.

   a. Coordinating Center: Responsibilities specific to the Coordinating Center include:

      • Adherence to the responsibilities delineated below for a Clinical Research Site.

      • Coordination and facilitation of at least 12 clinical trials at any given time after the first 12 months of the performance period.
• Development and maintenance of the consortium organizational structure.

• Provision of at least two initial Phase II or Phase I/II clinical trial protocols for implementation by the consortium within the first 3 months of the performance period.

• Management of consortium-developed procedures for review, selection, and implementation of clinical trials proposed by or through consortium members.

• Establishment and management of procedures to ensure compliance with the local institutional review boards (IRBs) of all sites for the conduct of clinical trials and the protection of human subjects.

• Establishment and management of procedures for ensuring compliance with U.S. Food and Drug Administration (FDA) requirements for investigational agents, devices, and procedures.

• Establishment and management of a communications plan and an ongoing communications system between the Coordinating Center and Clinical Research Sites.

• Management of consortium-developed quality assurance and quality control mechanisms for study monitoring, including:
  ○ Real-time and remote monitoring program.
  ○ Management plan for the handling, distribution, analysis, and banking of specimens and/or imaging products generated from consortium studies necessary for the conduct and analyses of clinical trials during the performance period of the award.
  ○ Registration, tracking, and reporting of participant accrual.
  ○ Timely medical review and assessment of participant data.
  ○ Rapid reporting and communication of adverse events.
  ○ Interim evaluation and consideration of measures of outcome.

• Management of consortium-developed comprehensive data collection and data management systems that addresses the needs of all sites in terms of access to data, data security, and data integrity measures.

• Development of statistical plans for all consortium clinical trials.

• Management of consortium-developed intellectual and material property issues among institutions participating in the consortium.

• Management of consortium-developed procedures for the timely publication of major findings and other public dissemination of data.
• Development and execution of a plan to establish financial independence from DoD funding by the end of the award period of performance.

• Development and execution of plans for ongoing review by the consortium’s External Advisory Board (EAB), to include participation by Government representatives. EAB reviews should be conducted no less than twice yearly.

b. Clinical Research Sites: The responsibilities of each site include:

• If required by the Government, participation in a pre-award planning meeting with all consortium members to discuss operational features of the consortium, the requirements for progress and evaluation, and the award negotiations process.

• Full participation in the consortium, including but not limited to, clinical trial introduction and selection, patient accrual for consortium studies (to include accrual from disproportionately affected populations), data collection and timely submissions, meeting attendance, and adherence to the consortium’s operating procedures.

• Presentation of at least two clinical trials for the consortium’s consideration per year. **For the Coordinating Center, this requirement is in addition to the initial two clinical trials required at the beginning of the award.**

• Meeting minimum accrual requirements of 25 patients per year, either independently or in partnership with other non-consortium institutions. At least 20% of these patients must be contributions to trials from other consortium sites, and at least 5% of all accrued patients at each site must be from disproportionately affected populations.

• Provision for a Clinical Research Coordinator who will interact with the Clinical Research Coordinators of other Clinical Research Sites and the Supervising Clinical Research Coordinator of the Coordinating Center to expedite and guide clinical protocols through the regulatory approval processes and to coordinate patient accrual and study activities across sites.

• Implementation of the consortium’s core data collection methodology and strategies.

• Compliance with consortium-developed quality assurance and quality control procedures, as appropriate, including:
  
  ○ Participation in a monitoring program to be managed by the Coordinating Center.
  
  ○ Implementation of the consortium-developed management plan for acquisition, delivery, and storage of biological samples and study data.
  
  ○ Submission of appropriate data and materials to allow for verification and review of protocol-related procedures, for example, pathology, imaging techniques, surgical methods, and therapeutic use.
• Implementation of procedures established by the Coordinating Center for ensuring compliance with FDA requirements for investigational agents, as appropriate.

• Implementation of procedures established by the Coordinating Center to meet the local IRB requirements for the conduct of clinical trials and the protection of human subjects.

• Serving as a resource for the conduct of protocol-specified laboratory projects (such as tumor biology studies).

• Participation in consortium-developed procedures for the timely publication of major findings.

• Participation in consortium-developed procedures for resolving intellectual and material property issues among institutions participating in the consortium.

• Participation in ongoing review by the consortium’s EAB.

• Submission of annual written progress reports, a final written comprehensive report, and any other reports required by the Government to be outlined in the assistance agreement.

• Additional responsibilities based on recommendations and guidance from the consortium EAB and U.S. Army Medical Research and Materiel Command (USAMRMC) staff.

2. **Performance Metrics:** Exercise of the options for continued performance of each participant site after the first year will be contingent upon meeting performance metrics as specified in the award agreements.

a. **Metrics for Coordinating Center Performance:**

• Completion of at least four trials in each 12-month period of the award period of performance.

• Maintain a portfolio of at least 12 open trials at any given time after the first 6 months of the period of performance.

• Successfully move agents for at least 20% of consortium trials forward for additional testing (e.g., Phase III), which ultimately have the potential to change clinical practice. **Note:** The Clinical Consortium Award is not intended to support the conduct of clinical trials that test the next logical iteration of an existing treatment.

• Enrollment of at least 5% of patients from disproportionately affected populations (e.g., African Americans, populations with compromised or limited access to health care) in consortium trials overall.

• Progress, as deemed acceptable by the Government, toward financial self-sufficiency.
b. Metrics for Clinical Research Site Performance:

- Accrual of at least 25 patients per year to consortium trials (excluding Phase III trials), either independently or in partnership with other non-consortium institutions. At least 20% of these patients must be contributions to trials from other consortium sites.

- Participation in a minimum of six trials initiated by other consortium sites over 3 years.

- Presentation of at least two trials per year or six trials over 3 years to the consortium for consideration.

- Accrual of at least 5% of patients from disproportionately affected populations (e.g., African Americans, populations with compromised or limited access to health care).

- Timely submission of quality data as outlined by the Coordinating Center.

3. External Advisory Board: To ensure optimal conduct and oversight of consortium activities, the Coordinating Center will propose and develop an EAB. Coordinating Center applications must include a description of the proposed EAB members, the role of each member (e.g., scientific, business, or other type of review), evidence of agreement to serve, and plans for interaction between the EAB and consortium members, which should, at a minimum, include meetings (whether in person or other means) no less than twice yearly. Support for this interaction must be included in the proposed Coordinating Center budget.

The Government reserves the right to require augmentation of the EAB membership prior to or during the award performance period. In addition, representatives of the PCRP, CDMRP, and/or the USAMRMC must be invited to participate in meetings involving the EAB. The Government reserves the right to direct the location of any in-person meeting. Support for Government participation should not be included in the proposed budget.

4. Plan for Financial Self-Sufficiency: It is expected that the consortium will be financially self-sufficient (i.e., able to continue operations without further DoD support) by the end of the award period. Coordinating Center applications must include a clear and detailed plan to achieve this goal.

5. Past Performance (if applicable): Applications from institutions that have previously received a PCRP Clinical Consortium Award must include a description of the past performance of the award, including compliance with the metrics of the previous award as well as other individual contributions made to consortium activities.

The CDMRP intends that information, data, and research resources generated under awards funded by this Program Announcement be made available to the research community (which includes both scientific and consumer advocacy communities) and to the public at large. For additional guidance, refer to the General Application Instructions, Appendix 2, Section K.
Awards will be made no later than September 30, 2018. For additional information refer to Section II.F.1, Federal Award Notices.

II.C. Eligibility Information

II.C.1. Eligible Applicants

II.C.1.a. Organization: All organizations, including international organizations, are eligible to apply.

Government Agencies within the United States: Local, state, and Federal Government agencies are eligible to the extent that applications do not overlap with their fully funded internal programs. Such agencies are required to explain how their applications do not overlap with their internal programs.

As applications for this Program Announcement may be submitted by extramural and intramural organizations, these terms are defined below.

Extramural Organization: An eligible non-DoD organization. Examples of extramural organizations include academia, biotechnology companies, foundations, Government, and research institutes. Extramural Submission: Application submitted by a non-DoD organization to Grants.gov.

Intramural DoD Organization: A DoD laboratory, DoD military treatment facility, and/or DoD activity embedded within a civilian medical center. Intramural Submission: Application submitted by a DoD organization for an intramural investigator who is a DoD military or civilian employee working within a DoD laboratory or military treatment facility or in a DoD activity embedded within a civilian medical center.

Note: Applications from an intramural organization or from an extramural non-DoD Federal organization may be submitted through a research foundation.

The USAMRAA makes awards to eligible organizations, not to individuals.

II.C.1.b. Principal Investigator

PIs must be independent investigators at or above the Assistant Professor level (or equivalent) at an eligible institution. Eligibility is not affected by previous receipt of a PCRP Clinical Consortium Award.

An eligible PI, regardless of ethnicity, nationality, or citizenship status, must be employed by, or affiliated with, an eligible organization.

The CDMRP encourages all PIs to participate in a digital identifier initiative through Open Researcher and Contributor ID, Inc. (ORCID). Registration for a unique ORCID identifier can be done online at http://orcid.org/.
II.C.2. Cost Sharing

Cost sharing/matching is not an eligibility requirement.

II.C.3. Other

Extramural organizations must be able to access .gov and .mil websites in order to fulfill the financial and technical deliverable requirements of the award and submit invoices for payment.

For general information on required qualifications for award recipients, refer to the General Application Instructions, Appendix 3.

Refer to Section II.H.2, Administrative Actions, for a list of administrative actions that may be taken if a pre-application or application does not meet the administrative, eligibility, or ethical requirements defined in this Program Announcement.

II.D. Application and Submission Information

Submission of applications that are essentially identical or propose essentially the same research project to different funding opportunities within the same program and fiscal year is prohibited and will result in administrative withdrawal of the duplicative application(s).

Extramural Submission is defined as an application submitted by a non-DoD organization to Grants.gov.

Intramural Submission is defined as an application submission by a DoD organization for an intramural investigator, who is a DoD military or civilian employee working within a DoD laboratory or military treatment facility, or working in a DoD activity embedded within a civilian medical center.

II.D.1. Address to Request Application Package

Submitting Extramural and Intramural Organizations: Pre-application content and forms can be accessed at the electronic Biomedical Research Application Portal (eBRAP) (https://eBRAP.org).

Submitting Extramural Organizations: Full application packages can be accessed at Grants.gov.

Submitting Intramural DoD Organizations: Full application packages can be accessed at eBRAP.org.

Contact information for the CDMRP Help Desk and the Grants.gov Contact Center can be found in Section II.G, Federal Awarding Agency Contacts.
II.D.2. Content and Form of the Application Submission

Submission is a two-step process requiring both pre-application and full application as indicated below. The submission process should be started early to avoid missing deadlines. There are no grace periods.

Pre-Application Submission: All pre-applications for both extramural and intramural organizations must be submitted through eBRAP (https://eBRAP.org/).

eBRAP is a multifunctional web-based system that allows PIs to submit their pre-applications electronically through a secure connection, to view and edit the content of their pre-applications and full applications, to receive communications from the CDMRP, and to submit documentation during award negotiations and period of performance.

Full Application Submission: Full applications must be submitted through the online portals as described below.

Submitting Extramural Organizations: Full applications from extramural organizations must be submitted through Grants.gov. Applications submitted by extramural organizations (e.g., research foundations) on behalf of intramural DoD or other Federal organizations or investigators will be considered extramural submissions.

Submitting Intramural DoD Organizations: Intramural DoD organizations may submit full applications to either eBRAP or Grants.gov. Intramural DoD organizations that are unable to submit to Grants.gov should submit through eBRAP. Intramural DoD organizations with the capability to submit through Grants.gov may submit following the instructions for extramural submissions through Grants.Gov or may submit to eBRAP. Applications from extramural organizations, including non-DoD Federal organizations, received through eBRAP will be withdrawn. See definitions in Section II.C.1, Eligible Applicants.

eBRAP allows intramural organizations to submit full applications following pre-application submission.

For both Extramural and Intramural applicants: A key feature of eBRAP is the ability of an organization’s representatives and PIs to view and modify the full application submissions associated with them. eBRAP will validate full application files against the specific Program Announcement requirements and discrepancies will be noted in an email to the PI and in the Full Application Files tab in eBRAP. It is the applicant’s responsibility to review all application components for accuracy as well as ensure proper ordering as specified in this Program Announcement.

The application title, eBRAP log number, and all information for the PI, Business Official(s), performing organization, and contracting organization must be consistent throughout the entire pre-application and application submission process. Inconsistencies may delay application processing and limit or negate the ability to view, modify, and verify the application in eBRAP. If any changes need to be made, the applicant should contact the CDMRP Help Desk at help@eBRAP.org or 301-682-5507 prior to the application deadline.
II.D.2.a. Step 1: Pre-Application Submission Content

During the pre-application process, each submission is assigned a unique log number by eBRAP. This unique eBRAP log number will be needed during the full application submission process.

To begin the pre-application process, first select whether the submitting organization is extramural or intramural, then confirm your selection or cancel. Incorrect selection of extramural or intramural submission type may result in delays in processing.

If an error has been made in the selection of extramural versus intramural and the pre-application submission deadline has passed, the PI or Business Official must contact the CDMRP Help Desk at help@eBRAP.org or 301-682-5507.

All pre-application components must be submitted by the PI through eBRAP (https://eBRAP.org/).

PIs and organizations identified in the pre-application should be the same as those intended for the subsequent application submission. If any changes are necessary after submission of the pre-application, the PI must contact the CDMRP Help Desk at help@eBRAP.org or 301-682-5507.

When starting the pre-application, PIs should ensure that they have selected the appropriate application category:

- Clinical Research Site, or
- Coordinating Center, or
- Coordinating Center with the option to be considered as a Clinical Research Site if the application is not selected for award as the single Coordinating Center.

The pre-application consists of the following components, which are organized in eBRAP by separate tabs (refer to the General Application Instructions, Section II.B, for additional information on pre-application submission):

- **Tab 1 – Application Information**

- **Tab 2 – Application Contacts**

Enter contact information for the PI. Enter the organization’s Business Official responsible for sponsored program administration (the “person to be contacted on matters involving this application” in Block 5 of the Grants.gov SF424 (R&R) Form). The Business Official must be either selected from the eBRAP list or invited in order for the pre-application to be submitted.

Select the performing organization (site at which the PI will perform the proposed work) and the contracting organization (organization submitting on behalf of the PI, which corresponds to Block 5 on the Grants.gov SF424 (R&R) Form), and click on “Add Organizations to this Pre-
application.” The organization(s) must be either selected from the eBRAP drop-down list or invited in order for the pre-application to be submitted.

It is recommended that PIs identify an Alternate Submitter in the event that assistance with pre-application submission is needed.

- **Tab 3 – Collaborators and Key Personnel**

Enter the name, organization, and role of all collaborators and key personnel associated with the application.

FY17 PCRP Programmatic Panel members should not be involved in any pre-application or application. For questions related to panel members and pre-applications or applications, refer to Section II.H.2.c, Withdrawal, or contact the CDMRP Help Desk at help@eBRAP.org or 301-682-5507.

To preserve the integrity of its peer and programmatic review processes, the CDMRP discourages inclusion of any employee of its review contractors having any role in pre-application or application preparation, research, or other duties for submitted pre-applications or applications. For FY17, the identities of the peer review contractor and the programmatic review contractor may be found at the CDMRP website (http://cdmrp.army.mil/about/2tierRevProcess). Pre-applications or applications that include names of personnel from either of these companies will be administratively withdrawn unless plans to manage conflicts of interest (COIs) are provided and deemed appropriate by the Grants Officer. Refer to the General Application Instructions, Appendix 3, for detailed information.

- **Tab 4 – Conflicts of Interest**

List all individuals other than collaborators and key personnel who may have a COI in the review of the application (including those with whom the PI has a personal or professional relationship). Refer to the General Application Instructions, Appendix 3, Section C, for further information regarding COIs.

- **Tab 5 – Pre-Application Files**

  - **Letter of Intent (LOI) (one-page limit):** Provide a brief description of the research to be conducted. LOIs are used for program planning purposes only (e.g., reviewer recruitment) and will not be reviewed during either the peer or programmatic review sessions.

- **Tab 6 – Submit Pre-Application**

This tab must be completed for the pre-application to be accepted and processed.
II.D.2.b. Step 2: Full Application Submission Content

All contributors and administrators to the application must use matching compatible versions of Adobe software when editing and preparing application components. The use of different software versions will result in corruption of the submitted file. Refer to the General Application Instructions, Section III, for details on compatible Adobe software.

The CDMRP cannot make allowances/exceptions to its policies for submission problems encountered by the applicant organization using system-to-system interfaces with Grants.gov.

Each application submission must include the completed full application package for this Program Announcement. The full application package is submitted by the Authorized Organizational Representative through Grants.gov (http://www.grants.gov/) for extramural organizations or through eBRAP (https://ebrap.org/) for intramural organizations. See Table 1 below for more specific guidelines.

II.D.2.b.i. Full Application Guidelines

Extramural organizations, including non-DoD Federal agencies, must submit full applications through Grants.gov. Submissions of extramural applications through eBRAP may be withdrawn.

Table 1. Full Application Submission Guidelines

<table>
<thead>
<tr>
<th>Extramural Submissions</th>
<th>Intramural DoD Submissions</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Application Package Location</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Full Application Package Components</strong></td>
<td></td>
</tr>
<tr>
<td><strong>SF424 (R&amp;R) Application for Federal Assistance Form:</strong> Refer to the General Application Instructions, Section III.A.1, for detailed information.</td>
<td><strong>Tab 1 – Summary:</strong> Provide a summary of the application information. <strong>Tab 2 – Application Contacts:</strong> This tab will be pre-populated by eBRAP; add Authorized Organizational Representative.</td>
</tr>
<tr>
<td>Descriptions of each required file can be found under Full Application Submission Components:</td>
<td></td>
</tr>
<tr>
<td>• Attachments</td>
<td>Tab 3 – Full Application Files: Upload files under each Application Component in eBRAP. Descriptions of each required file can be found under Full Application Submission Components:</td>
</tr>
<tr>
<td>• Research &amp; Related Senior/Key Person Profile (Expanded)</td>
<td>• Attachments</td>
</tr>
<tr>
<td>• Research &amp; Related Budget</td>
<td>• Key Personnel</td>
</tr>
<tr>
<td>• Project/Performance Site Location(s) Form</td>
<td>• Budget</td>
</tr>
<tr>
<td>• R&amp;R Subaward Budget Attachment(s) Form (if applicable)</td>
<td>• Performance Sites</td>
</tr>
<tr>
<td>Extramural Submissions</td>
<td>Intramural DoD Submissions</td>
</tr>
<tr>
<td>------------------------</td>
<td>---------------------------</td>
</tr>
<tr>
<td><strong>Tab 4 – Application and Budget Data:</strong></td>
<td>Review and edit proposed project start date, proposed end date, and budget data pre-populated from the Budget Form.</td>
</tr>
</tbody>
</table>

**Application Package Submission**

<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>If either the Project Narrative or the budget fails eBRAP validation or if the Project Narrative or the budget need to be modified, an updated Grants.gov application package must be submitted via Grants.gov as a “Changed/Corrected Application” with the previous Grants.gov Tracking ID prior to the application submission deadline.</td>
<td>Tab 5 – Submit/Request Approval Full Application: After all components are uploaded and prior to the full application submission deadline, enter your password in the space provided “Enter Your Password Here” and press the “Submit Full Application” button. eBRAP will notify your Resource Manager/Comptroller or equivalent Business Official by email to log into eBRAP to review and to approve prior to the application submission deadline.</td>
</tr>
</tbody>
</table>

**Application Verification Period**

| The full application package submitted to Grants.gov may be viewed and modified in eBRAP until the end of the application verification period. During the application verification period, the full application package, with the exception of the Project Narrative and Budget Form, may be modified. | After eBRAP has processed the full application, the organizational Resource Manager/Comptroller or equivalent Business Official and PI will receive an email notification of this status and will be able to view and modify application components in eBRAP. During the application verification period, the full application package, with the exception of the Project Narrative and Budget Form, may be modified. |

**Further Information**

| Refer to the General Application Instructions, Section III, for further information regarding Grants.gov requirements. | Refer to the General Application Instructions, Section IV, for further information regarding eBRAP requirements. |

_The organization’s Business Official or Authorized Organization Representative (or Resource Manager/Comptroller) should approve/verify the full application submission prior to the application verification deadline._

Application viewing, modification, and verification in eBRAP are strongly recommended, but not required. _The Project Narrative and Budget cannot be changed after the application submission deadline._ Prior to the full application deadline, a corrected or modified full application package may be submitted. Other application components may be changed until the
end of the application verification period. After the end of the application verification period, the full application cannot be modified.

*Material submitted after the end of the application verification period, unless specifically requested by the Government, will not be forwarded for processing.*

The full application package must be submitted using the unique eBRAP log number to avoid delays in application processing.

**II.D.2.b.ii. Full Application Submission Components:**

- **Extramural Applications Only –**
  
  **SF424 (R&R) Application for Federal Assistance Form:** Refer to the General Application Instructions, Section III.A.1, for detailed information.

- **Extramural and Intramural Applications –**
  
  **Attachments:**

  *Each attachment to the full application components must be uploaded as an individual file in the format specified and in accordance with the formatting guidelines listed in the General Application Instructions, Appendix 4.*

  For all attachments, ensure that the file names are consistent with the guidance. Attachments will be rejected if the file names are longer than 50 characters or incorrect file names that contain characters other than the following: A-Z, a-z, 0-9, underscore, hyphen, space, and period. In addition, there are file size limits that may apply in some circumstances. Individual attachments may not exceed 20 MB and the file size for the entire full application package may not exceed 200 MB.

  - **Attachment 1: Project Narrative (60-page limit for the Coordinating Center plus Clinical Research Site; 20-page limit for each Clinical Research Site):** Upload as “ProjectNarrative.pdf.” The page limit of the Project Narrative applies to text and non-text elements (e.g., figures, tables, graphs, photographs, diagrams, chemical structures, drawings) used to describe the project. Inclusion of URLs that provide additional information to expand the Project Narrative and could confer an unfair competitive advantage is prohibited and may result in administrative withdrawal of the application.

  Describe the proposed project in detail using the outline below.

  - **Coordinating Center (40-page limit):** It is the PI’s responsibility to clearly articulate the ability of his or her group to serve as the consortium Coordinating Center and support the design and conduct of consortium clinical trials.

    Describe the qualifications of the group and plans for the development of key features of the consortium Coordinating Center using the following general outline:
(1) **Commitment to and Experience in Multidisciplinary and Multi-Institutional Prostate Cancer Clinical Research:** Describe previous experience and accomplishments related to the design, administration, and fiscal management of multi-institutional prostate cancer clinical trials, with particular emphasis on Phase II, of high-impact, novel therapeutic agents or approaches for the management or treatment of prostate cancer. Describe previous experience with establishing communications systems and data management resources for multi-institutional projects. Reference relevant publications and submit reprints with the application. If the institution is a previous recipient of a PCRP Clinical Consortium Award, whether as Coordinating Center or Clinical Research Site, a description of the past performance of that award must be included.

(2) **Institutional Resources:** Provide evidence of institutional commitment to provide the necessary resources needed to develop and support standardized data collection, data management and analysis, and data security and integrity for the consortium participants.

(3) **Consortium Organizational Structure:** Provide a detailed description of the overall consortium organization, plans for ongoing communications, procedures for transference of funds, and standardized operating procedures for selection and implementation of clinical trials. The organizational structure should include the following key features:

- Coordinating Center for administration and day-to-day management of consortium operations; developing the clinical trial selection process, protocol coordination; regulatory coordination; study management and monitoring; data collection, management, and statistics; intellectual/material property coordination; and performance as a Clinical Research Site.

- Clinical Research Sites for conceiving, developing, and conducting clinical trials in prostate cancer, as well as serving as entry points for clinical trials from outside the consortium.

- Clinical Consortium Committee composed of the PIs from the Coordinating Center and Clinical Research Sites, for the clinical trial selection process and for the continual development and operation of the consortium. A representative from the USAMRMC is to be invited to all official meetings for the Clinical Consortium Committee.

- A proposed EAB for scientific review, oversight, data monitoring, and evaluation. Include a description of the proposed EAB members, the role of each member (e.g., scientific, business, or other type of review), evidence of agreements to serve, and plans for interaction between the EAB and consortium members, which should, at a minimum, include meetings (whether in person or other means) no less than twice yearly.
• Plans for ongoing communications among Clinical Research Sites and between Clinical Research Sites and the Coordinating Center; plans should address methods for information distribution within the consortium, and how information technologies will be used to (1) facilitate routine multi-institutional communication and (2) provide ongoing communication and data sharing.

• A proposed set of performance metrics for the Coordinating Center and for the Clinical Research Sites.

(4) **Clinical Trials Implementation:** Describe plans for coordinating the submission, review, selection, and implementation of clinical trials within the consortium.

• Outline plans for coordinating IRB submissions and approvals at participating sites.

• Outline plans for developing procedures to ensure compliance with FDA requirements for investigational agents, as appropriate.

(5) **Study Management and Monitoring:** Describe plans for ongoing communication among all institutions participating in the consortium.

• Include a named Supervising Clinical Research Coordinator who will interact with and oversee the Clinical Research Site clinical coordinators to guide clinical protocols through the regulatory approval processes, coordinate participant accrual, and coordinate study activities across sites.

• Outline procedures for quality assurance, quality control, and study monitoring.

• Describe plans for the development of methods for the handling, distribution, analysis, banking, and security of specimens and/or imaging products generated from consortium-sponsored studies.

(6) **Data Management:** Outline a strategy for the development and implementation of a comprehensive data management and statistical analysis plan, including:

• Descriptions of the overall approach to data collection and management.

• A statistical plan that includes methods to monitor quality and consistency of data collection and methods to measure outcomes.

• A plan for ongoing data transfer.

• Data security and integrity measures.
(7) **Publication and Data Dissemination:** Describe plans for ensuring rapid publication and other public dissemination of data while maintaining participant privacy.

(8) **Fiscal Administration:** Describe previous experience with the financial management of multi-institutional clinical research studies. Outline a detailed strategy for achieving financial self-sufficiency of the consortium by the end of the performance period for the Clinical Consortium Award.

(9) **Two Initial Clinical Trials:** Start section on a new page; **10-page limit for this section within the 40-page limit for the Coordinating Center portion.** Provide brief descriptions of two currently funded Phase II or Phase I/II prostate cancer clinical trials proposed to be implemented by the consortium within the first 3 months of the award period. It is expected that most, if not all, of the patients for these studies will be accrued from within the consortium. Therefore, the two initial clinical trials must be ready to initiate patient accrual just prior to or at the initiation of the award. The proposed studies will be evaluated at both peer and programmatic reviews.

Include the following information for each of the two proposed clinical trials:

- **Clinical trial title:** Provide the title of each clinical trial.
- **Phase:** Designate the clinical trial as Phase I/II or II.
- **Personnel:** List the names of all personnel (including the PI) who will have significant involvement in the clinical trials; include their practice license(s) (e.g., M.D. or R.N.), highest degree(s), job title(s), and employing institution(s).
- **Location of study:** List all centers, clinics, or laboratories where the studies are to be conducted; include details as to how consortium Clinical Research Sites will be integrated into these trials.
- **Background:** Describe the rationale for conducting the study, as well as the study’s relevance and applicability of findings; include descriptions of preliminary studies, Phase I results, or other findings.
- **Objectives:** Describe the purpose, goals, and endpoint of the study.
- **Drug or device:** Describe the drugs or devices to be used in the studies; include Investigational New Drug (IND)/Investigational Device Exemption (IDE) numbers, sponsors, and sources, if applicable.
- **Study population:** Describe the target population and the proposed sample size and provide patient accrual rate requirements.
• Protocol design: Describe the type of study to be performed (prospective, retrospective, randomized, controlled, etc.) and outline the proposed methodology.

• Funding and IRB approval status: Provide evidence of funding status of the initial clinical trial(s); describe the status of IRB approval for the initial clinical trial(s).

b. All Sites (Coordinating Center and Clinical Research Sites) (20-page limit): It is the responsibility of the PI to clearly articulate the qualifications of the research team and institution to participate as a Clinical Research Site in the consortium.

Provide evidence that the research team and institution fulfill each of the following criteria for participation in the consortium:

(1) **Commitment to and experience in prostate cancer clinical research**

If the institution is a previous recipient of a PCRP Clinical Consortium Award, whether as Coordinating Center or Clinical Research Site, a description of the performance of that award must be included, with emphasis on the individual contribution of the institution to consortium activities.

• Describe the PI’s commitment to prostate cancer clinical research, which may include levels of effort, funding, and interactions with consumer advocacy groups.

• Describe the PI’s experience in conducting multi-institutional clinical trials that demonstrate willingness and ability to function in the consortium.

• Describe specific areas of clinical research interest, such as novel drugs, combinatorial therapy schedules, surgical interventions, imaging techniques, and immunotherapies. Include overall scope of program and demonstration of integration of basic and/or correlative science into the program.

• Provide details of ongoing or completed prostate cancer-relevant clinical trials, particularly Phase II clinical trials, with an emphasis on clinical trials that might be brought into the consortium. Reference relevant publications and submit reprints with the application.

• Describe procedures for ensuring compliance with FDA requirements for investigational agents.

• Provide evidence of willingness to resolve intellectual and material property issues.
(2) **Consortium resources**

- Include a **named** institutional Clinical Research Coordinator, who will interact with the Clinical Research Coordinators at other consortium Clinical Research Sites and the Supervising Clinical Research Coordinator at the Coordinating Center, to guide clinical protocols through the regulatory approval processes, coordinate participant accrual, and coordinate study activities across sites.

- Describe the available prostate cancer population (including size, age range, and clinical manifestations) and provide evidence of ability to accrue prostate cancer patients into consortium-sponsored studies. Include documentation of access to and ability to recruit patients from disproportionately affected populations and any other special patient populations, such as those in the Military Health System.

- Provide evidence of successful multi-center clinical trial collaborations.

(3) **Institutional resources**

- Provide evidence of expertise in clinical trials within the applicant institution and describe experience in the development and conduct of prostate cancer clinical trials; as appropriate, describe any additional multidisciplinary clinical and/or laboratory expertise that could serve as the basis for the development of clinical trials by the consortium.

- Describe the resources and expertise available for the collection and processing of specimens from consortium-sponsored studies.

- Describe the resources and expertise for data management and maintenance of data security/confidentiality.

- Provide evidence of institutional commitment to providing facilities and resources in the conduct of consortium operations.

- **Attachment 2: Supporting Documentation (Coordinating Center and Clinical Research Sites):** Combine and upload as a single file named “Support.pdf.” Start each document on a new page. If documents are scanned to PDF, the lowest resolution (100 to 150 dpi) should be used. The Supporting Documentation attachment should not include additional information such as figures, tables, graphs, photographs, diagrams, chemical structures, or drawings. These items should be included in the Project Narrative. Any additional material viewed as an extension of the Project Narrative will be removed or may result in administrative withdrawal of the application.

*There are no page limits for any of these components unless otherwise noted. Include only those components described below; inclusion of items not requested will result in the removal of those items or may result in administrative withdrawal of the application.*
- References Cited: List the references cited (including URLs, if available) in the Project Narrative using a standard reference format that includes the full citation (i.e., author[s], year published, title of reference, source of reference, volume, chapter, page numbers, and publisher, as appropriate).

- List of Abbreviations, Acronyms, and Symbols: Provide a list of abbreviations, acronyms, and symbols.

- Facilities, Existing Equipment, and Other Resources: Describe the facilities and equipment available for performance of the proposed project and any additional facilities or equipment proposed for acquisition at no cost to the award. Indicate whether or not Government-furnished facilities or equipment are proposed for use. If so, reference should be made to the original or present Government award under which the facilities or equipment items are now accountable. There is no form for this information.

- Publications and/or Patents: Include a list of relevant publication URLs and/or patent abstracts. If publications are not publicly available, then copies of up to five published manuscripts may be included in Attachment 2. Extra items will not be reviewed.

- Letters of Organizational Support: Provide a letter (or letters, if applicable), signed by the Department Chair or appropriate organization official, confirming the laboratory space, equipment, and other resources available for the project. Letters of support not requested in the Program Announcement, such as those from members of Congress, do not impact application review or funding decisions.

- Letters of Collaboration (if applicable): Provide a signed letter from each collaborating individual or organization that will demonstrate that the PI has the support or resources necessary for the proposed work. If an investigator at an intramural organization is named as a collaborator on an application submitted through an extramural organization, the application must include a letter from the collaborator’s Commander or Commanding Officer at the intramural organization that authorizes the collaborator’s involvement.

  - Intellectual and Material Property Plan (if applicable): Provide a plan for resolving intellectual and material property issues among participating organizations.
  
  - Note: As this award supports consortium infrastructure and does not provide direct support for the clinical research, certain types of intellectual property may not be relevant to this application and need not be discussed.
Commercialization Strategy (if applicable): Describe the commercialization plan. The plan should include intellectual property, market size, financial analysis, strengths and weaknesses, barriers to the market, competitors, and management team. Discuss the significance of this development effort, when it can be anticipated, and the potential commercial use for the technology being developed.

- Clinical Trial Funding and Approval Documentation (Coordinating Center applications only): Provide documentation of funding and IRB approval status for the two initial clinical trials.

  o Attachment 3: Technical Abstract (one-page limit): Upload as “TechAbs.pdf.” The technical abstract is used by all reviewers. Abstracts of all funded research projects will be posted publicly. Do not include proprietary or confidential information. Use only characters available on a standard QWERTY keyboard. Spell out all Greek letters, other non-English letters, and symbols. Graphics are not allowed.

  Describe the proposed consortium or, for Clinical Research Site applications, specific participation in the consortium including the following elements:

  - Background: Present the ideas and reasoning behind the proposed effort.
  - Objective/Hypothesis: State the objectives to be achieved. Provide evidence that supports the feasibility.
  - Specific Aims: State the specific aims.
  - Study Design: Briefly describe the types of clinical trials to be proposed for conduct by the consortium.
  - Clinical Impact: Briefly describe how the proposed consortium, or participation in the consortium, may lead to a major impact on prostate cancer clinical management.

  o Attachment 4: Lay Abstract (one-page limit): Upload as “LayAbs.pdf.” The lay abstract is used by all reviewers. Abstracts of all funded research projects will be posted publicly. Do not include proprietary or confidential information. Use only characters available on a standard QWERTY keyboard. Spell out all Greek letters, other non-English letters, and symbols. Graphics are not allowed.

  The lay abstract is required for Coordinating Center applicants only. Lay abstracts should be written using the outline below. Do not duplicate the technical abstract. Minimize use of acronyms and abbreviations, where appropriate. The lay abstract is an important component of the application review process because it addresses issues of particular interest to the consumer advocate community.

  - Describe the scientific objectives and rationale for the proposed consortium in a manner that will be readily understood by readers without a background in science or medicine.
- Describe the ultimate applicability of the research.
- What types of patients will it help, and how will it help them?
- What are the potential clinical applications, benefits, and risks?
- What is the projected time it may take to achieve an impact on the standard of care for prostate cancer?
- What are the likely contributions of this study to advancing the field of prostate cancer research?

**Attachment 5: Statement of Work (SOW) (three-page limit):** Upload as “SOW.pdf.”

The suggested SOW format and examples specific to different types of research projects are available on the eBRAP “Funding Opportunities & Forms” web page (https://ebrap.org/eBRAP/public/Program.htm). For the Clinical Consortium Award mechanism, use the SOW format example titled “SOW (Statement of Work) Generic Format.” The SOW must be in PDF format prior to attaching.

The SOW should include a list of major tasks that support the proposed specific aims, followed by a series of subtasks outlined related to the major tasks and milestones within the period of performance. The SOW should describe only the work for which funding is being requested by this application and, as applicable, should also:

- Include the name(s) of the key personnel and contact information for each study site/subaward site.
- Indicate the number (and type, if applicable) of research subjects (animal or human) and/or human anatomical samples projected or required for each task and at each site. Refer to the General Application Instructions, Appendix 1, for additional information regarding regulatory requirements.
- Briefly state the methods to be used.
- For studies with prospective accrual of human subjects, indicate quarterly enrollment targets.
- Identify cell line(s) and commercial or organizational source(s) to be used. If human anatomical substances (including cell lines) will be used, specify whether or not identifiable information is accessible to the research team by any means.
- If applicable, indicate timelines required for regulatory approvals relevant to human subjects research (e.g., Investigational New Drug and Investigational Device Exemption applications) by the U.S. Food and Drug Administration or other Government agency.

**Attachment 6: Impact Statement (one-page limit):** Upload as “Impact.pdf.” Describe how the PI and other personnel will contribute to the productive operations of the
consortium and have an impact moving high-impact, novel therapeutic agents or approaches for the management or treatment of prostate cancer to clinical practice.

Explain in detail why the proposed project is important, as follows:

**Describe the short-term impact:** Detail the anticipated outcomes that will be directly attributed to the results of the proposed project, including a description of the target populations. Explain how these results/outcome(s)/product(s) will have the potential to transform prostate cancer management and change clinical practice.

**Describe the long-term impact:** Explain the long-term gains from the proposed project, including how the outcomes or products will ultimately contribute to the elimination of death from prostate cancer and enhancing the well-being of men experiencing the impact of the disease.

**PCRP Overarching Challenges:** Summarize how the proposed research will address any or all of the PCRP Overarching Challenges.

- **Attachment 7: Data and Research Resource Sharing Plan (one-page limit):** Upload as “Sharing.pdf.” Describe how unique and/or final research data will be shared with the wider prostate cancer research community, along with any resulting research resources. This includes cases where pre-existing data or research resources will be utilized and/or modified during the course of the award. If there are limitations associated with a pre-existing agreement for the original data or research resources that preclude subsequent sharing, the applicant should explain this in the data- and/or research resource-sharing plan.

Refer to the General Application Instructions, Appendix 2, Section K, for additional information.

In preparing requested budgets, applicants may include anticipated costs associated with data- and research resource-sharing (i.e., making a large dataset available to the public or developing an important resource for the scientific community).

- **Attachment 8: DoD Military Budget Form(s), if applicable:** Upload as “MFBudget.pdf.” If a military facility (military health system facility, research laboratory, treatment facility, dental treatment facility, or a DoD activity embedded with a civilian medical center) will be a collaborator in performance of the project, complete the DoD Military Budget Form, available for download on the eBRAP “Funding Opportunities & Forms” web page (https://ebrap.org/eBRAP/public/Program.htm), including a budget justification, for each military facility as instructed. The costs per year should be included on the Grants.gov Research and Related Budget form under subaward costs. Refer to the General Application Instructions, Section III.A.7, for detailed information.
Extramural and Intramural Applications –

Research & Related Senior/Key Person Profile (Expanded): For extramural submissions (via Grants.gov), refer to the General Application Instructions, Section III.A.3, and for intramural submissions (via eBRAP), refer to the General Application Instructions, Section IV.A.2, for detailed information.

○ PI Biographical Sketch (five-page limit): Upload as “Biosketch_LastName.pdf.” The suggested biographical sketch format is available on the “Funding Opportunities & Forms” web page (https://ebrap.org/eBRAP/public/Program.htm) in eBRAP. The National Institutes of Health Biographical Sketch may also be used. All biographical sketches should be submitted in the portable document format (PDF) that is not editable.

○ PI Previous/Current/Pending Support (no page limit): Upload as “Support_LastName.pdf.”

○ Key Personnel Biographical Sketches (five-page limit each): Upload as “Biosketch_LastName.pdf.”

○ Key Personnel Previous/Current/Pending Support (no page limit): Upload as “Support_LastName.pdf.”

Research & Related Budget: For extramural submissions (via Grants.gov), refer to the General Application Instructions, Section III.A.4, and for intramural submissions (via eBRAP), refer to the General Application Instructions, Section IV.A.3, for detailed information.

Budget Justification (no page limit): Upload as “BudgetJustification.pdf.” The budget justification for the entire period of performance must be uploaded to the Research & Related Budget after completion of the budget for Period 1.

Project/Performance Site Location(s) Form): For extramural submissions (via Grants.gov), refer to the General Application Instructions, Section III.A.5, and for intramural submissions (via eBRAP), refer to the General Application Instructions, Section IV.A.4, for detailed information.

Extramural Applications Only –

R&R Subaward Budget Attachment(s) Form (if applicable): Refer to the General Application Instructions, Section III.A.6, for detailed information.

○ Extramural Subaward: Complete the Research & Related Subaward Budget Form through Grants.gov. (Refer to the General Application Instructions, Section III.A.6, for detailed information.)

○ Intramural DoD Collaborator(s): Complete the DoD Military Budget Form and upload to Grants.gov as Attachment 8. (Refer to the General Application Instructions, Section III.A.7, for detailed information.) Intramural DoD Collaborator(s) costs per year
should be included on the Grants.gov Research and Related Budget form under subaward costs.

II.D.3. Dun and Bradstreet Universal Numbering System (DUNS) Number and System for Award Management (SAM)

Applicant organizations and all subrecipient organizations must have a DUNS number to submit applications to Grants.gov. The applicant organization must also be registered in the Entity Management functional area of the SAM with an “Active” status to submit applications through the Grants.gov portal. Verify the status of the applicant’s organization’s Entity registration in SAM well in advance of the application submission deadline. Allow 3 to 4 weeks to complete the entire SAM registration process. If an applicant has not fully complied with the requirements by the time the Federal awarding agency is ready to make a Federal award, the Federal awarding agency may determine that the applicant is not qualified to receive a Federal award and use that determination as a basis for making a Federal award to another applicant. Refer to the General Application Instructions, Section III, for further information regarding Grants.gov requirements.

II.D.4. Submission Dates and Times

All submission dates and times are indicated in Section I, Overview of the Funding Opportunity. Pre-application and application submissions are required. The pre-application and application submission process should be started early to avoid missing deadlines. There are no grace periods. Failure to meet either of these deadlines will result in submission rejection.

Applicant Verification of Full Application Submission in eBRAP

Prior to the end of the application verification period, PIs and organizational representatives can review and modify in eBRAP certain components of a submitted application. Following retrieval and processing of the full application, eBRAP will notify the organizational representatives and PI by email to log into eBRAP to review, modify, and verify the full application submission. eBRAP will validate retrieved files against the specific Program Announcement requirements and discrepancies will be noted in both the email and in the Full Application Files tab in eBRAP. eBRAP does not confirm the accuracy of file content. It is the applicant’s responsibility to review all application components and ensure proper ordering as specified in the Program Announcement. If either the Project Narrative or the budget fails eBRAP validation or needs to be modified, an updated full application package must be submitted prior to the application submission deadline. The Project Narrative and Budget Form cannot be changed after the application submission deadline.

II.D.5. Funding Restrictions

The PCRP plans to invest a total of $8.4M in the FY17 PCRP Clinical Consortium Award over a 3-year period. A total of $2.8M will be allocated from the FY17 PCRP budget to fund the first year of performance. Options will be included for continued performance in subsequent years, with $2.8M expected from each of the FY18 and FY19 PCRP budgets to fund the options. The initial performance period of the award and each option period will be for 12 months. Exercise of the options for continued performance is contingent on receipt of sufficient Congressional appropriations for the PCRP in FY18–FY19 and acceptable performance by the recipients.
The purpose of the PCRP Clinical Consortium Award is to provide the funding to establish the necessary collaborations and resources to rapidly execute clinical trials by the consortium. This award will not fund research or development of clinical protocols.

**Coordinating Center**

- The maximum period of performance is 3 years.
- The anticipated direct costs budgeted for the entire period of performance will not exceed $3,600,000 plus indirect costs. These funds are for all Coordinating Center functions, both administrative and clinical, as described in this Program Announcement. Indirect cost rates are to be budgeted in accordance with the organization’s negotiated rate. No budget will be approved by the Government exceeding $3,600,000 direct costs or using an indirect cost rate exceeding the organization’s negotiated rate.
- All direct and indirect costs of any subaward or contract must be included in the total direct costs of the primary award.

**Clinical Research Sites**

- The period of performance is 3 years.
- The anticipated direct costs budgeted for the entire period of performance will not exceed $600,000 plus indirect costs for each Clinical Research Site. Indirect cost rates are to be budgeted in accordance with the organization’s negotiated rate. No budget will be approved by the Government exceeding $600,000 direct costs or using an indirect cost rate exceeding the organization’s negotiated rate.
- All direct and indirect costs of any subaward or contract must be included in the total direct costs of the primary award.

*Exercise of the options* for continued performance for each Clinical Research Site after the first year will be contingent upon meeting the performance metrics as outlined in the [Section II.B, Award Information](#), and upon receipt of sufficient Congressional appropriations to the PCRP for FY18 and FY19.

All direct and indirect costs of any subaward or contract must be included in the total direct costs of the primary award.

For this award mechanism, direct costs for the Coordinating Center must be requested for:

- Travel for attendance at EAB review meetings (including costs for all appropriate personnel), to be held a minimum of two times per year. Costs should also be included for conducting these meetings.
- Travel for the PI and up to four additional members of the research team to attend a 1-day meeting to be held in the National Capital Area each year during the award period of performance. This meeting will be held to provide a presentation on progress.
The travel costs required above are in addition to those allowed for annual scientific/technical meetings.

May be requested for (not all-inclusive):

- Salary support for personnel needed to meet the goals of the consortium, such as the PI, Supervising Clinical Research Coordinator, Administrative Assistant(s), Research Nurse(s), Statistician(s), Database Manager, and Informatics Manager
- Consortium-related meetings, teleconferences, and travel among participating investigators
- Database generation, software development, and website design
- Purchase of computers, specialized software, and specialized software licenses pertinent to Coordinating Center-specific responsibilities for use at participating institutions
- Costs related to establishing financial independence (e.g., fees for legal consultation)
- Other costs directly associated with planning and developing the consortium collaborations and resources
- Travel costs for up to two investigators to travel to two scientific/technical meetings per year. The Government reserves the right to direct the selection of one of these meetings, should a PCRP-sponsored meeting be convened during the award period of performance.

Direct costs for Clinical Research Sites must be requested for:

- Travel for attendance at EAB review meetings (including costs for all appropriate personnel), to be held a minimum of two times per year.
- Travel costs for up to two investigators to travel to two scientific/technical meetings per year. The Government reserves the right to direct the selection of one of these meetings, should a PCRP-sponsored meeting be convened during the award period of performance.

May be requested for (not all inclusive):

- Salary support for personnel needed to meet the goals of the consortium such as the PI, Clinical Research Coordinator, Research Nurse, and Data/Informatics Coordinator
- Consortium-related meetings, teleconferences, and travel among participating institutions
- Computers and general software required to participate in the consortium
- Other costs directly associated with planning and developing the consortium

Cost sharing and utilization of other funding sources are encouraged.

Extramural (non-Federal) awards will consist solely of assistance agreements (Cooperative Agreements and Grants). For extramural awards with an intragovernmental component, direct
transfer of funds from an extramural award recipient to a DoD or other Federal agency is not allowed except under very limited circumstances. Funding to intramural DoD and other Federal agencies will be managed through a direct fund transfer. Intragovernmental only funding to intramural DoD and other Federal agencies will be managed through a direct fund transfer. Intramural applicants are responsible for coordinating through their agency’s procedures the use of contractual or assistance funding awards or other appropriate agreements to support extramural collaborators.

Refer to the General Application Instructions, Section III.A.4, for budget regulations and instructions for the Research & Related Budget. For Federal agencies or organizations collaborating with Federal agencies, budget restrictions apply as are noted in the General Application Instructions, Section III.A.4.

The CDMRP expects to allot approximately $2.8M of the $90M FY17 PCRP appropriation to fund approximately one Clinical Consortium – Coordinating Center and two Clinical Consortium – Clinical Research Site Award applications, depending on the quality and number of applications received. Funding of applications received in response to this Program Announcement is contingent upon the availability of Federal funds for this program.

II.D.6. Other Submission Requirements

Refer to the General Application Instructions, Appendix 4, for detailed formatting guidelines.

II.E. Application Review Information

II.E.1. Criteria

II.E.1.a. Peer Review

To determine technical merit, all applications will be evaluated according to the following scored criteria:

a. Coordinating Center (to be reviewed in addition to the All Sites criteria below): All Coordinating Center applications will be evaluated according to the following criteria. Of these, Personnel, Consortium Components, and Study and Data Management are equally the most important, with the remaining criteria listed in decreasing order of importance.

- Personnel
  - How well the PI or other key personnel have demonstrated appropriate expertise in prostate cancer and in the design and administration of multi-institutional prostate cancer clinical trials.
  - Whether the PI and key personnel have previous success in acquiring funding for clinical trials.
  - Whether the Supervising Clinical Research Coordinator, who will interact with all Clinical Research Coordinators, possesses the appropriate expertise to coordinate regulatory approvals and consortium activities.
• **Consortium Components**
  
  ○ Whether the application includes all required consortium components (e.g., EAB, Clinical Consortium Committee, Coordinating Center, and Clinical Research Sites, including affiliates).
  
  ○ How well the proposed EAB has been developed.
  
  ○ How well the components as proposed will function as an integrated unit.

• **Study and Data Management**
  
  ○ How the strategies for the development and implementation of data management and statistical plans will provide access to data, data security, and data integrity.
  
  ○ Whether there is an outline of an appropriate study management plan, including plans for ongoing communication, quality control, and quality assurance.
  
  ○ Whether there are appropriate plans for the development of specimen handling, distribution, analysis, and banking methods.
  
  ○ Whether there are appropriate plans for rapid publication and other public dissemination of data generated by the consortium.
  
  ○ Whether all relevant privacy issues have been addressed appropriately.

• **Financial Management**
  
  ○ Whether the PI and/or other key personnel have appropriate experience and expertise in fiscal administration of multisite studies, including the distribution and management of funds.
  
  ○ How well the Coordinating Center personnel demonstrate ability and commitment to achieving financial self-sufficiency of the consortium by the end of the award period.

• **Coordinating Center Two Initial Clinical Trials**
  
  ○ **Personnel (applicable if a clinical trial(s) originates from outside the Coordinating Center and key personnel have not been previously listed)**
    
    – Whether the PI and other key personnel in the clinical trial have been named and whether they have the appropriate expertise in prostate cancer.
    
    – Whether the PI has a proven record of success in completing clinical trials.

  ○ **Study Design**
    
    – Whether the trials are focused on potentially high-impact, novel, therapeutic interventions.
− Whether the study population has been adequately described.
− Whether the investigational drugs or devices have been adequately described.
− If from outside the Coordinating Center, whether the initiating institution(s) possess the appropriate qualifications.
− Whether the proposed timelines indicate increased efficiency as a result of consortium participation.

○ **Regulatory Process**
− Whether the trials will be ready for initiation at a time appropriate for implementation by the consortium.
− Whether there are appropriate plans for the coordination of IRB submissions and approvals at participating sites.
− Whether there is an appropriate plan for developing procedures to ensure compliance with FDA regulations for investigational agents.
− Whether the appropriate IND/IDE numbers been provided.

○ **Impact**
− Whether the trials address an important problem in prostate cancer.
− To what extent the intervention or device to be tested, if the study is successful, will have a significant impact on prostate cancer.
− Whether the types of studies proposed are appropriate.

**b. All Sites (Clinical Research Sites and Coordinating Center):** All applications will be evaluated according to the following criteria, which are of equal importance.

- **Personnel**
  - Whether the PI meets the eligibility requirements.
  - How the research team’s background and expertise are appropriate with respect to its ability to perform multi-institutional prostate cancer clinical research.
  - To what extent the research team has the ability and experience to contribute substantially to the design and conduct of consortium clinical trials.
  - Whether the named institutional Clinical Research Coordinator has the appropriate experience in guiding clinical protocols through the regulatory approval processes.
and the ability to foster communication with other consortium Clinical Research Coordinators.

○ Whether there are appropriate levels of effort for successful conduct of the proposed work.

○ If applicable, whether the description of past performance of a previously received PCRP Clinical Consortium Award demonstrates successful achievement of previous award metrics and other substantive individual contributions to consortium activities.

• **Institutional Resources and Commitment**
  
  ○ Whether the institution has demonstrated appropriate commitment to working with the consortium.

  ○ How the PI is supported by the availability of and accessibility to facilities and resources, especially in regard to specimen collection and processing.

  ○ Whether the institution possesses appropriate resources and expertise for data management and maintaining security and confidentiality.

  ○ How well the institution has demonstrated its willingness and ability to resolve intellectual and material property issues with other institutions in the consortium.

  ○ Whether the institution has unique resources that may be of benefit to the consortium.

• **Participant Recruitment**

  ○ Whether the PI has demonstrated sufficient access to the appropriate prostate cancer patient population(s).

  ○ Whether the PI has provided sufficient evidence of access to and ability to recruit patients from disproportionately affected populations.

  ○ Whether the PI has provided evidence of access to and ability to recruit patients from other special populations, such as those from the Military Health System (if applicable).

  ○ Whether the institution has proven success in recruiting patients for clinical trials.

• **Collaborations**

  ○ Whether the PI has demonstrated appropriate background, expertise, and success in collaborative prostate cancer clinical research.

  ○ How well the PI will integrate into the consortium and be a contributing member.

  ○ How well the PI’s institution has facilitated the PI’s collaborations.
In addition, the following unscored criteria will also contribute to the overall evaluation of the application:

- **Budget**
  - Whether the *direct* maximum costs are equal to or less than the allowable direct maximum costs as published in the Program Announcement.
  - Whether the budget is appropriate for the proposed research.

- **Application Presentation**
  - To what extent the writing, clarity, and presentation of the application components influence the review.

**II.E.1.b. Programmatic Review**

To make funding recommendations and select the application(s) that, individually or collectively, will best achieve the program objectives, the following criteria are used by programmatic reviewers:

- Ratings and evaluations of the peer reviewers
- Relevance to the mission of the DHP and FY17 PCRP, as evidenced by the following:
  - Adherence to the intent of the award mechanism
  - Programmatic relevance in relation to the FY17 PCRP Overarching Challenges and Focus Areas
  - Relative impact
  - Program portfolio composition

**II.E.2. Application Review and Selection Process**

All applications are evaluated by scientists, clinicians, and consumers in a two-tier review process. The first tier is peer review of applications against established criteria for determining technical merit. Each application is evaluated for its own merit, independent of other applications. The second tier is a programmatic review that makes recommendations for funding to the Commanding General, USAMRMC, on behalf of the DHA and the OASD(HA), based on technical merit, the relevance to the mission of the DHP, and PCRP, the specific intent of the award mechanism, and to other specified evaluation criteria in the Program Announcement. Programmatic review is a comparison-based process in which applications with scientific and technical merit compete in a common pool. *The highest-scoring applications from the first tier of review are not automatically recommended for funding. Funding recommendations depend on various factors as described in Section.II.E.1.b, Programmatic Review.* Additional
information about the two-tier process used by the CDMRP can be found at http://cdmrp.army.mil/about/fundingprocess.

All CDMRP review processes are conducted confidentially to maintain the integrity of the merit-based selection process. Panel members sign a statement that application and evaluation information will not be disclosed outside the panel. Violations of confidentiality can result in the dissolving of a panel(s) and other corrective actions. In addition, personnel at the applicant or collaborating organizations are prohibited from contacting persons involved in the review process to gain protected evaluation information or to influence the evaluation process. Violations of these prohibitions will result in the administrative withdrawal of the organization’s application. Violations by panel members or applicants that compromise the confidentiality of the review process may also result in suspension or debarment from Federal awards. Furthermore, the unauthorized disclosure of confidential information of one party to another third party is a crime in accordance with 18 USC 1905.

II.E.3. Integrity and Performance Information

Prior to making an assistance agreement award where the Federal share is expected to exceed the simplified acquisition threshold (currently $150,000) over the period of performance, the Federal awarding agency is required to review and consider any information about the applicant that is available in the Federal Awardee Performance and Integrity Information System (FAPIIS).

An applicant, at its option, may review FAPIIS, accessible through SAM, and submit comments to FAPIIS on any information about itself that a Federal awarding agency previously entered and is currently available in FAPIIS.

The Federal awarding agency will consider any comments by the applicant, in addition to other information in the designated integrity and performance system, in making a judgment about the applicant’s integrity, business ethics and record of performance under Federal awards when determining a recipient’s qualification prior to award, according to the qualification standards of the Department of Defense Grant and Agreement Regulations (DoDGAR), Section 22.415.

II.E.4. Anticipated Announcement and Federal Award Dates

All application review dates and times are indicated in Section I, Overview of the Funding Opportunity.

Each PI and organization will receive email notification of posting of the funding recommendation in eBRAP. Each PI will receive a peer review summary statement on the strengths and weaknesses of the application.

II.F. Federal Award Administration Information

II.F.1. Federal Award Notices

Awards will be made no later than September 30, 2018. Refer to the General Application Instructions, Appendix 2, for additional award administration information.
Awards are made to organizations, not to individual PIs. The types of awards made under the Program Announcement will be assistance agreements (grants or cooperative agreements). The level of involvement on the part of DoD during project performance is the key factor in determining whether to award a grant or cooperative agreement.

**Extramural Organizations:** An assistance agreement (grant or cooperative agreement) is appropriate when the Federal Government transfers a “thing of value,” to a “state, local government,” or “other recipient,” to carry out a public purpose of support or stimulation authorized by a law of the United States, instead of acquiring property or service for the direct benefit and use of the U.S. Government. An assistance agreement can take the form of a grant or cooperative agreement. If “no substantial involvement” on the part of the funding agency is anticipated, a grant award will be made (31 USC 6304). Conversely, if substantial involvement on the part of the funding agency is anticipated, a cooperative agreement will be made (31 USC 6305). Substantial involvement may include collaboration, participation, or intervention in the research to be performed under the award. The award type, along with the start date, will be determined during the negotiation process.

After email notification of application review results through the eBRAP, and if selected for funding, a representative from the USAMRAA will contact the business official authorized to negotiate on behalf of the PI’s organization.

Only an appointed USAMRAA Grants Officer may obligate the Government to the expenditure of funds. No commitment on the part of the Government should be inferred from discussions with any other individual. The award document signed by the Grants Officer is the official authorizing documents.

**Intramural Organizations:** Awards to Federal Government organizations (to include intramural DoD organizations) will be executed through the Military Interdepartmental Purchase Request (MIPR) or Funding Authorization Document (FAD) process. Transfer of funds is contingent upon appropriate safety and administrative approvals. Intramural applicants and collaborators are reminded to coordinate receipt and commitment of funds through their respective resource managers (RM).

After email notification of application review results through the eBRAP, and if selected for funding, a representative from the CDMRP will contact the business official authorized to negotiate on behalf of the PI’s organization.

**II.F.1.a. Award Transfers**

Changes in PI are not allowed, except under extenuating circumstances that will be evaluated on a case-by-case basis and at the discretion of the Grants Officer.

Organizational transfers will not be allowed for the Coordinating Center or Clinical Research Sites under the Clinical Consortium Award mechanism.

Refer to the General Application Instructions, Appendix 2, Section B, for general information on organization or PI changes.
II.F.1.b. Pre-Award Meeting

At the Government’s discretion, the PI and Clinical Study Coordinator or other personnel may be requested to participate in a pre-award meeting at the Government’s expense.

II.F.2. Administrative and National Policy Requirements

Attendance is required at a 1-day meeting to be held in the National Capital Area for the purpose of reporting on progress. Additional in-person presentations may be requested.

At the discretion of the Government, each participant site may be expected to participate in an on-site audit by the Government or its designee.

Applicable requirements in the DoDGAR found in 32 CFR, Chapter 1, Subchapter C, and 2 CFR, Chapter XI, apply to grants and cooperative agreements resulting from this Program Announcement.

Refer to the General Application Instructions, Appendix 2, for general information regarding administrative requirements.

Refer to the General Application Instructions, Appendix 5, for general information regarding national policy requirements.

Refer to full text of the USAMRAA General Research Terms and Conditions for Institutions of Higher Education, Hospitals, and Non-Profit Organizations and the USAMRAA General Research Terms and Conditions with For-Profit Organizations for further information.

II.F.3. Reporting

Refer to the General Application Instructions, Appendix 2, Section A, for general information on reporting requirements. Annual progress reports as well as a final progress report will be required.

In addition to written progress reports, Annual Award Charts will be required. For the CCA mechanism, use the format example titled, “Generic Award Charts,” available on the eBRAP “Funding Opportunities & Forms” web page (https://ebrap.org/eBRAP/public/Program.htm).

Awards resulting from this Program Announcement will incorporate additional reporting requirements related to recipient integrity and performance matters. Recipient organizations that have Federal contract, grant, and cooperative agreement awards with a cumulative total value greater than $10,000,000 are required to provide information to FAPIIS about certain civil, criminal, and administrative proceedings that reached final disposition within the most recent 5-year period and that were connected with performance of a Federal award. Recipients are required to disclose semiannually information about criminal, civil, and administrative proceedings as specified in the applicable Terms and Conditions. The applicable Terms and Conditions for institutions of higher education, hospitals, and nonprofit organizations is available in OAR Article I, Section B, in the July 2016 R&D General Terms and Conditions. The applicable Terms and Conditions for for-profit organizations is available in Section 34 of the
II.G. Federal Awarding Agency Contacts

II.G.1. CDMRP Help Desk

Questions related to Program Announcement content or submission requirements as well as questions related to the pre-application or intramural application submission through eBRAP should be directed to the CDMRP Help Desk, which is available Monday through Friday from 8:00 a.m. to 5:00 p.m. ET. Response times may vary depending upon the volume of inquiries.

   Phone: 301-682-5507

   Email: help@eBRAP.org

II.G.2. Grants.gov Contact Center

Questions related to extramural application submission through Grants.gov portal should be directed to the Grants.gov Contact Center, which is available 24 hours a day, 7 days a week (closed on U.S. Federal holidays). Note that the CDMRP Help Desk is unable to provide technical assistance with Grants.gov submission.

   Phone: 800-518-4726; International 1-606-545-5035

   Email: support@grants.gov

Sign up on Grants.gov for “send me change notification emails” by following the link on the Synopsis page for the Program Announcement or by responding to the prompt provided by Grants.gov when first downloading the Grants.gov application package. If the Grants.gov application package is updated or changed, the original version of the application package may not be accepted by Grants.gov.

II.H. Other Information

II.H.1. Program Announcement and General Application Instructions Versions

Questions related to this Program Announcement should refer to the Program name, the Program Announcement name, and the Program Announcement version code 20170516b. The Program Announcement numeric version code will match the General Applications Instructions version code 20170516.

II.H.2. Administrative Actions

After receipt of applications, the following administrative actions may occur:
II.H.2.a. Rejection

The following will result in administrative rejection of the application:

- Pre-application was not submitted.
- Project Narrative exceeds page limit.
- Project Narrative is missing.
- Budget is missing.

II.H.2.b. Modification

- Pages exceeding the specific limits will be removed prior to review for all documents other than the Project Narrative.
- Documents not requested will be removed.

II.H.2.c. Withdrawal

The following may result in administrative withdrawal of the application:

- An FY17 PCRP Programmatic Panel member is named as being involved in the research proposed or is found to have assisted in the pre-application or application processes including, but not limited to, concept design, application development, budget preparation, and the development of any supporting documentation. A list of the FY17 PCRP Programmatic Panel members can be found at [http://cdmrp.army.mil/pcrp/panels/panel17](http://cdmrp.army.mil/pcrp/panels/panel17).

- The application fails to conform to this Program Announcement description to the extent that appropriate review cannot be conducted.

- Inclusion of URLs, with the exception of links in References Cited and Publication and/or Patent Abstract sections.

- Page size is larger than 8.5 inches x 11.0 inches (approximately 21.59 cm x 27.94 cm).

- To preserve the integrity of its peer and programmatic review processes, the CDMRP discourages inclusion of any employee of its review contractors having any role in the preparation, research or other duties for submitted applications. For FY17, the identities of the peer review contractor and the programmatic review contractor may be found at the CDMRP website ([http://cdmrp.army.mil/about/2tierRevProcess](http://cdmrp.army.mil/about/2tierRevProcess)). Applications that include names of personnel from either of these companies will be administratively withdrawn unless plans to manage COIs are provided and deemed appropriate by the Grants Officer. Refer to the General Application Instructions, Appendix 3, for detailed information.

- Personnel from applicant or collaborating organizations are found to have contacted persons involved in the review process to gain protected evaluation information or to influence the evaluation process.
• Applications from extramural organizations, including non-DoD Federal agencies, received through eBRAP may be withdrawn.

• Applications submitted by an intramural DoD organization may be withdrawn if the intramural organization cannot coordinate the use of contractual, assistance, or other appropriate agreements to provide funds to extramural collaborators.

• An application for which the PI does not meet the eligibility criteria will be withdrawn.

• Submission of the same research project to different Funding Opportunities within the same program and fiscal year.

II.H.2.d. Withhold

Applications that appear to involve research misconduct will be administratively withheld from further consideration pending organizational investigation. The organization will be required to provide the findings of the investigation to the USAMRAA Grants Officer for a determination of the final disposition of the application.
**II.H.3. Application Submission Checklist**

<table>
<thead>
<tr>
<th>Application Components</th>
<th>Action</th>
<th>Completed</th>
</tr>
</thead>
<tbody>
<tr>
<td>SF424 (R&amp;R) Application for Federal Assistance <strong>(Extramural submissions only)</strong></td>
<td>Complete form as instructed.</td>
<td></td>
</tr>
<tr>
<td>Summary (Tab 1) and Application Contacts (Tab 2) <strong>(Intramural submissions only)</strong></td>
<td>Complete these tabs as instructed.</td>
<td></td>
</tr>
<tr>
<td><strong>Attachments</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Project Narrative: Upload as Attachment 1 with file name “ProjectNarrative.pdf.”</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Supporting Documentation: Upload as Attachment 2 with file name “Support.pdf.”</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Technical Abstract: Upload as Attachment 3 with file name “TechAbs.pdf.”</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lay Abstract: Upload as Attachment 4 with file name “LayAbs.pdf.”</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Statement of Work: Upload as Attachment 5 with file name “SOW.pdf.”</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Impact Statement: Upload as Attachment 6 with file name “Impact.pdf.”</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Data and Research Resource Sharing Plan: Upload as Attachment 7 with file name “Sharing.pdf.”</td>
<td></td>
<td></td>
</tr>
<tr>
<td>DoD Military Budget Form(s): Upload as Attachment 8 with file name “MFBudget.pdf,” if applicable.</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Research &amp; Related Senior/Key Person Profile (Expanded)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Attach PI Biographical Sketch (Biosketch_LastName.pdf) to the appropriate field.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Attach PI Previous/Current/Pending Support (Support_LastName.pdf) to the appropriate field.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Attach Biographical Sketch (Biosketch_LastName.pdf) for each senior/key person to the appropriate field.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Attach Previous/Current/Pending Support (Support_LastName.pdf) for each senior/key person to the appropriate field.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>**Research &amp; Related Budget <strong>(Extramural submissions only)</strong></td>
<td>Complete as instructed. Attach Budget Justification (BudgetJustification.pdf) to the appropriate field.</td>
<td></td>
</tr>
<tr>
<td>**Budget <strong>(Intramural submissions only)</strong></td>
<td>Complete the DoD Military Budget Form and justification.</td>
<td></td>
</tr>
<tr>
<td>Project/Performance Site Location(s) Form</td>
<td>Complete form as instructed.</td>
<td></td>
</tr>
<tr>
<td>R&amp;R Subaward Budget Attachment(s) Form, if applicable</td>
<td>Complete form as instructed.</td>
<td></td>
</tr>
</tbody>
</table>
## APPENDIX 1: ACRONYM LIST

<table>
<thead>
<tr>
<th>Acronym</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACURO</td>
<td>Animal Care and Use Review Office</td>
</tr>
<tr>
<td>B</td>
<td>Billion</td>
</tr>
<tr>
<td>CDMRP</td>
<td>Congressionally Directed Medical Research Programs</td>
</tr>
<tr>
<td>CFR</td>
<td>Code of Federal Regulations</td>
</tr>
<tr>
<td>DHA</td>
<td>Defense Health Agency</td>
</tr>
<tr>
<td>DHP</td>
<td>Defense Health Program</td>
</tr>
<tr>
<td>DoD</td>
<td>Department of Defense</td>
</tr>
<tr>
<td>DoDGAR</td>
<td>Department of Defense Grant and Agreement Regulations</td>
</tr>
<tr>
<td>DUNS</td>
<td>Data Universal Numbering System</td>
</tr>
<tr>
<td>eBRAP</td>
<td>Electronic Biomedical Research Application Portal</td>
</tr>
<tr>
<td>EAB</td>
<td>External Advisory Board</td>
</tr>
<tr>
<td>EC</td>
<td>Ethics Committee</td>
</tr>
<tr>
<td>ET</td>
<td>Eastern Time</td>
</tr>
<tr>
<td>FAD</td>
<td>Funding Authorization Document</td>
</tr>
<tr>
<td>FAPIIS</td>
<td>Federal Awardee Performance and Integrity Information System</td>
</tr>
<tr>
<td>FDA</td>
<td>U.S. Food and Drug Administration</td>
</tr>
<tr>
<td>FY</td>
<td>Fiscal Year</td>
</tr>
<tr>
<td>HRPO</td>
<td>Human Research Protection Office</td>
</tr>
<tr>
<td>IDE</td>
<td>Investigational Device Exemption</td>
</tr>
<tr>
<td>IND</td>
<td>Investigational New Drug</td>
</tr>
<tr>
<td>IRB</td>
<td>Institutional Review Board</td>
</tr>
<tr>
<td>LOI</td>
<td>Letter of Intent</td>
</tr>
<tr>
<td>M</td>
<td>Million</td>
</tr>
<tr>
<td>MIPR</td>
<td>Military Interdepartmental Purchase Request</td>
</tr>
<tr>
<td>OASD(HA)</td>
<td>Office of the Assistant Secretary of Defense for Health Affairs</td>
</tr>
<tr>
<td>ORCID</td>
<td>Open Researcher and Contributor ID, Inc.</td>
</tr>
<tr>
<td>ORP</td>
<td>Office of Research Protections</td>
</tr>
<tr>
<td>PCRP</td>
<td>Prostate Cancer Research Program</td>
</tr>
<tr>
<td>PI</td>
<td>Principal Investigator</td>
</tr>
<tr>
<td>RDT&amp;E</td>
<td>Research, Development, Test, and Evaluation</td>
</tr>
<tr>
<td>RM</td>
<td>Resource Manager</td>
</tr>
<tr>
<td>SAM</td>
<td>System for Award Management</td>
</tr>
<tr>
<td>SOW</td>
<td>Statement of Work</td>
</tr>
<tr>
<td>USAMRAA</td>
<td>U.S. Army Medical Research Acquisition Activity</td>
</tr>
<tr>
<td>USAMRMC</td>
<td>U.S. Army Medical Research and Materiel Command</td>
</tr>
<tr>
<td>USC</td>
<td>United States Code</td>
</tr>
</tbody>
</table>